BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27334313)

  • 1. RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases.
    Denbo JW; Yamashita S; Passot G; Egger M; Chun YS; Kopetz SE; Maru D; Brudvik KW; Wei SH; Conrad C; Vauthey JN; Aloia TA
    J Gastrointest Surg; 2017 Jan; 21(1):68-77. PubMed ID: 27334313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
    Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
    Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
    Brudvik KW; Mise Y; Chung MH; Chun YS; Kopetz SE; Passot G; Conrad C; Maru DM; Aloia TA; Vauthey JN
    Ann Surg Oncol; 2016 Aug; 23(8):2635-43. PubMed ID: 27016292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
    Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
    Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival.
    Lillemoe HA; Kawaguchi Y; Passot G; Karagkounis G; Simoneau E; You YN; Mehran RJ; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    J Gastrointest Surg; 2019 Jan; 23(1):84-92. PubMed ID: 30084064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat Hepatectomy for Recurrent Colorectal Liver Metastases: Is it Worth the Challenge?
    Ali MA; Di Sandro S; Lauterio A; Concone G; Mangoni I; Ferla F; Rotiroti V; Cusumano C; Giacomoni A; De Carlis L
    J Gastrointest Surg; 2015 Dec; 19(12):2192-8. PubMed ID: 26361773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
    Kemeny NE; Chou JF; Capanu M; Gewirtz AN; Cercek A; Kingham TP; Jarnagin WR; Fong YC; DeMatteo RP; Allen PJ; Shia J; Ang C; Vakiani E; D'Angelica MI
    Cancer; 2014 Dec; 120(24):3965-71. PubMed ID: 25155157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
    Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
    J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
    Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
    Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Complication Index Predicts Cancer-specific Survival After Resection of Colorectal Metastases Independent of RAS Mutational Status.
    Yamashita S; Sheth RA; Niekamp AS; Aloia TA; Chun YS; Lee JE; Vauthey JN; Conrad C
    Ann Surg; 2017 Dec; 266(6):1045-1054. PubMed ID: 27735824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.
    Amikura K; Akagi K; Ogura T; Takahashi A; Sakamoto H
    J Surg Oncol; 2018 Mar; 117(4):745-755. PubMed ID: 29194647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases.
    Kobayashi S; Takahashi S; Nomura S; Kojima M; Kudo M; Sugimoto M; Konishi M; Gotohda N; Taniguchi H; Yoshino T
    Cancer Med; 2021 Oct; 10(20):6998-7011. PubMed ID: 34535965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
    Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation Status of
    Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
    Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
    Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological diaphragmatic invasion by colorectal liver metastases is associated with RAS mutation, peritoneal recurrence and worse survival.
    Okuno M; Gourmard C; Mizuno T; Omichi K; Tzeng CD; Chun YS; Lee JE; Vauthey JN; Conrad C
    HPB (Oxford); 2018 Jan; 20(1):57-63. PubMed ID: 28943395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
    Newhook TE; Overman MJ; Chun YS; Dasari A; Tzeng CD; Cao HST; Raymond V; Parseghian C; Johnson B; Nishioka Y; Kawaguchi Y; Uppal A; Vreeland TJ; Jaimovich A; Arvide EM; Cristo JV; Wei SH; Raghav KP; Morris VK; Lee JE; Kopetz S; Vauthey JN
    Ann Surg; 2023 May; 277(5):813-820. PubMed ID: 35797554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.